French liver disorder specialist Genfit SA has announced the pricing of its Nasdaq IPO of ADS and European private placement.

Evotec AG and The Mark Foundation for Cancer Research have inked a R&D collaboration aimed at  developing novel immunooncological drugs

US-Austrian arenavirus-based cancer and infectious diseases specialist Hookipa has  has filed a prospectus for an US$86M Nasdaq IPO.

Neophore Limited, a cancer immuno-oncology company, today announces the appointment of Dr John Haurum as Non-Executive Director with immediate effect.

The EU’s Big Pharma companies have sharply criticised the European Parliament’s Legal Committee JURI backing of an amended proposal of the European Commission (EC) to introduce a supplementary protection certificates (SPC) manufacturing waiver. Under the waiver, EU-based biosimilar and generics makers would be allowed to export copycat drugs during the SPC period that adds five years of additional IP protection to the 20 years of patent duration.

A research team from Germany and Mexico has successfully  targeted uveal melanoma (UM), the most common type of eye cancer.

Pfizer Inc has paid €45m upfront to French gene therapy specalist Vivet Therapeutics in a licence option deal for Vivet’s preclinical Wilson disease candidate VTX-801. 

After positive preliminary results of Sotio’s SOV02 trial in ovarian cancer had been presented last year, the final analysis confirmed the survival benefits. The Czech biotech company now plans to initiate a global Phase III study with its autologous cell-based immunotherapy also in this indication.

More than 330 experts joined the 2-day AMR Conference 2019 in Berlin. They called for rapid capital investments and economic incentives in the fight against antimicrobial resistance (AMR).

Data presented at the 24th AKI & CRRT conference, suggest that the kidney function marker pro-enkephalin (penKid) is capable to rule out acute kidney injury (AKI) with a single measurement.